Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Pain Reduction in Adult Patients with Limb Spasticity Following a Single IncobotulinumtoxinA Injection: an Analysis of Pooled Data from Phase 2 and 3 Studies
Movement Disorders
P14 - Poster Session 14 (11:45 AM-12:45 PM)
5-008
IncobotulinumtoxinA (incoA) has shown pain-relieving benefits in patients (pts) with limb spasticity in individual studies; data from large pt cohorts are lacking.
To assess pain relief in a large cohort of incobotulinumtoxinA-treated pts with spasticity-associated pain (SAP) using pooled data from mostly placebo-controlled phase 2/3 studies.
Pain severity was assessed with the Disability Assessment Scale (DAS; 0–3) in adults with upper limb SAP. A ≥1 point reduction in the DAS pain score from baseline [BL] to 4 weeks was defined as response. Between-treatment group response rates (overall and by BL pain severity – DAS mild, moderate, severe) and the proportion of pts with complete pain relief (DAS pain score=0) at 4 weeks after 1 injection of incoA (total dose ≤400U) or placebo were analyzed using χ2 test. Overall between-group response rate differences were analyzed using logistic regression (presented as odds ratio [OR] and 95% confidence interval [CI]).
542 (incoA: 413, placebo: 129) pts reported SAP at BL. At 4 weeks, a significantly higher proportion of incoA- vs placebo-treated pts achieved a response (52.1% vs 28.7%; p<0.0001). IncoA-treated pts were more likely to achieve pain response vs placebo-treated pts (OR 2.7 [95% CI:1.6–4.3]; p<0.0001). Irrespective of BL pain severity, significantly higher response rates were observed with incoA vs placebo at 4 weeks (p<0.02 all comparisons). Complete pain relief was achieved by significantly more incoA- vs placebo-treated pts at 4 weeks (26.9% vs 12.4%; p=0.0007).
Pts receiving incoA vs placebo are significantly, by 2.7 times, more likely to achieve reduced upper limb SAP, irrespective of baseline pain severity, at 4 weeks post-injection thus supporting use of incoA in this setting.
Authors/Disclosures
Jorg Wissel
PRESENTER
Jorg Wissel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Jorg Wissel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Jorg Wissel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Jorg Wissel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. Jorg Wissel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merz. Jorg Wissel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Ipsen. Jorg Wissel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medtronic.
Alexandre Camoes-Barbosa, Jr., MD (Centro Hospitalar Universitario de Lisboa Central) Dr. Camoes-Barbosa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MERZ, ABBVIE, IPSEN. Dr. Camoes-Barbosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MERZ, ABBVIE, IPSEN.
Georg Comes, Other (Merz Therapeutics) Mr. Comes has received personal compensation for serving as an employee of Merz Pharmaceuticals GmbH.
Michael Althaus (Merz Pharmaceuticals GmbH) Michael Althaus has received personal compensation for serving as an employee of Merz Pharmaceuticals.
Astrid Scheschonka Astrid Scheschonka has received personal compensation for serving as an employee of Merz Therapeutics.
David M. Simpson, MD, FAAN (Icahn School of Medicine at Mount Sinai) Dr. Simpson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Simpson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz.